Drugs / HPV9v
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03626467 | Oct 2018 → Jul 2021 | HIV infectious disease | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV9v | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03626467 ↗ |
| Modality | Vaccine | “Patients will be treated with HPV9v vaccine at baseline, week 8 and week 24” NCT03626467 ↗ |